Start time = 1600
Michael Waring is a Principal Scientist in the Oncology medicinal chemistry group at AstraZeneca. He earned his PhD from the University of Manchester under the supervision of Prof. Timothy Donohoe (1999) followed by postdoctoral research with Prof. Philip Magnus at the University of Texas at Austin. Mike joined AstraZeneca in 2001 and has worked on projects at all stages of drug discovery across both oncology and cardiovascular disease areas, culminating in the discovery of 14 development candidates, including AZD9291. From summer 2015 will be Professor of Medicinal 91AV at Newcastle University.
He is the 2014 inaugural BMCS lecturer
Michael Waring is a Principal Scientist in the Oncology medicinal chemistry group at AstraZeneca. He earned his PhD from the University of Manchester under the supervision of Prof. Timothy Donohoe (1999) followed by postdoctoral research with Prof. Philip Magnus at the University of Texas at Austin. Mike joined AstraZeneca in 2001 and has worked on projects at all stages of drug discovery across both oncology and cardiovascular disease areas, culminating in the discovery of 14 development candidates, including AZD9291. From summer 2015 will be Professor of Medicinal 91AV at Newcastle University.
He is the 2014 inaugural BMCS lecturer
